Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH CML 2022 | Rationale for targeting leukemic stem cells with PDL1 antibodies or IRAK inhibitors

Toshio Kitamura • 21 Oct 2022
ESH CML 2022
Chronic Myeloid Leukemia Leukemia Imatinib

Toshio Kitamura, MD, PhD, The University of Tokyo, Tokyo, Japan, outlines the rationale for targeting leukemic stem cells with PDL1 antibodies or IRAK inhibitors in combination with imatinib in chronic myeloid leukemia (CML). Prof. Kitamura explains that leukemic stem cells have been shown to express PDL1 after imatinib treatment. Therefore, targeting PDL1 could improve the eradication of CML stem cells and increase the rate of patients eligible for treatment discontinuation. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Advisor for Rigel.

More from Toshio Kitamura

2:18
Immune dysregulation and clonal hematopoiesis in MDS
Toshio Kitamura • 21 Oct 2022
1:07
The impact of BCR-ABL mutations on signaling pathway activation in CML
Toshio Kitamura • 21 Oct 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals